Figure 1 | British Journal of Cancer

Figure 1

From: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

Figure 1

miR-204 expression is significantly associated with neuroblastoma disease subtypes and patient survival. (A) Box and whiskers plots represent the expression of miR-204 in a cohort of 143 primary neuroblastoma tumours. Samples are grouped according to known risk factors and miR-204 expression is compared between MYCN amplified (MYCNA) vs non-MYCNA, 11 LOH vs non-11q LOH, and INSS stages. Statistical differences in median expression were analysed using two-sided Mann–Whitney U tests. Dark shading indicates known higher-risk factor. (B) Expression of miR-204 in higher-risk INSS stages 3 and 4 vs lower-risk stages 1, 2, 4S, and in high-risk INSS stage 4 vs stage 1, 2, 3, 4S tumours. Samples are further grouped according to the presence of MYCNA and/or 11q LOH (MYCNA/11q-) and non-MYCNA and 11q LOH (designated as ‘other’). (C, D) Kaplan–Meier plots for EFS and OS in 143 neuroblastoma patients, with miR-204 expression > or < median. P-values were obtained using log-rank test. (E) Kaplan–Meier plots for EFS in high-risk INSS stage 4 disease (n=72) with miR-204 expression > or < median. (F) Kaplan–Meier plots for EFS in lower-risk INSS stage 1, 2, 3, 4S disease (n=71) with miR-204 expression>or<median. Abbreviation: HR=hazard ratio.

Back to article page